Hi needle, your last two posts have been nicely prosecuted to show that it is possible for paxalisib to receive an accelerated FDA approval for the treatment of GBM in about 18 months from now. My thoughts exactly.
Well informed KZIA investors in the US have been accumulating Kazia shares, with no corresponding volume sell down.
IMO, Kazia's valuation will have a major re-rating in the next 18 months, based on the paxalisib FDA approval, licensing agreements and further positive data readouts.
I still cannot get my head around the option for big pharma to simply take over Kazia at the right price.
Regards.
- Forums
- ASX - By Stock
- KZA
- Dr Priscilla Brastianos
Dr Priscilla Brastianos, page-167
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online